Turning Point Brands (TPB): Can It Reclaim the $100 Level After a Sharp Pullback?

Key Takeaways

• Turning Point Brands recently traded near $75, placing the $100 target roughly 33% above current levels — a meaningful but not unrealistic gap.
• The $100 mark is a natural psychological milestone, and TPB traded well above it as recently as early 2026, peaking near $147 in February.
• The strongest bull case rests on rapid growth in nicotine pouches under the FRE and ALP brands, supported by repeated analyst price-target increases.
• Key risks include a sharp valuation reset, intensifying competition in oral nicotine, and regulatory uncertainty at the FDA.
• Wall Street's consensus 12-month target sits near $125, implying analysts expect TPB to reclaim $100; the debate is really about the path and the timeline.

The Appeal of the $100 Milestone

Turning Point Brands, Inc. (TPB) is a consumer products company best known for Zig-Zag rolling papers and cigar wraps, Stoker's moist snuff, and a fast-growing portfolio of nicotine pouches. After a powerful rally that carried the stock to a 52-week high of $146.90 in late February 2026, shares have pulled back sharply and recently closed around $75.22.

That retreat has reignited a familiar investor question: can TPB reclaim the psychologically important $100 level? The figure is appealing because it is a round number, because the stock has already traded comfortably above it, and because it sits below the Street's consensus price target — making it a realistic checkpoint rather than a moonshot. I checked this setup using Tickeron’s AI Trend Prediction Engine to gauge the broader momentum.

Where TPB Stands Today

TPB's sharp decline from its February peak reflects a meaningful de-rating. The stock's trailing price-to-earnings (P/E) ratio now sits around 33 times earnings, while its 52-week range spans $65.80 to $146.90. In other words, even after the correction, the shares have not fallen to their low point of the year, but they are closer to that floor than to their former high.

That positioning matters for the $100 question. A return to triple digits would require a gain of roughly 33% from current levels — substantial, but far less dramatic than the move already delivered during the stock's earlier surge.

Catalysts That Could Push TPB Higher

The most important catalyst is the company's pivot toward modern oral nicotine. TPB's FRE brand and the newer ALP line have become the primary growth engine, and management has repeatedly raised full-year guidance as pouch sales accelerate. In late 2025, the company lifted its Modern Oral revenue outlook and delivered quarterly results that exceeded Wall Street's revenue and EBITDA expectations.

That momentum has translated directly into a stream of analyst upgrades. Oppenheimer has maintained an Outperform rating while raising its target from $110 to $120, and Alliance Global Partners lifted its Buy-rated target from $103 to $110. More recently, Needham upgraded the shares with a $125 target. The consensus 12-month price target across covering analysts now sits near $125, with a high estimate around $140 — comfortably above the $100 level in question.

Risks That Could Hold TPB Back

Several obstacles stand between TPB and $100. First, the stock's valuation is not obviously cheap after its run, and the sharp correction suggests some investors view the earlier multiple as unsustainable. Second, the nicotine pouch category is highly competitive, with deep-pocketed rivals aggressively expanding their own oral-nicotine offerings, which could pressure TPB's market share and pricing over time.

Regulatory risk is the third and perhaps most persistent concern. The U.S. Food and Drug Administration (FDA) retains significant authority over nicotine products, and any adverse action on pouch marketing or authorizations could disrupt growth assumptions. Each of these factors could slow the momentum needed to reclaim triple-digit territory.

Key Technical Levels to Watch

From a technical analysis perspective, the 52-week low near $65.80 represents the clearest downside support level, while the round-number $100 mark acts as both a psychological target and a potential resistance level once approached. Between them, the stock's recent trading range has provided no firm intermediate floor, meaning a sustained move toward $100 would likely require buyers to defend progressively higher levels rather than relying on a single catalyst.

What Analysts Are Saying

The analyst community is broadly constructive. With an average rating described as a Strong Buy and a consensus target near $125, the prevailing view already assumes TPB will trade above $100 within the next twelve months. That does not guarantee the outcome, but it does mean the $100 objective is consistent with — and in fact below — mainstream analyst expectations, rather than a contrarian or aggressive forecast.

My Take on TPB's Path Forward

Can TPB reach $100? The evidence suggests the target is realistic over a twelve-month horizon, primarily because the company's nicotine-pouch growth remains intact and Wall Street's consensus already anticipates a move above that level. The strongest supporting factors are accelerating Modern Oral sales, repeated guidance increases, and a steady series of analyst price-target raises.

The primary risks are equally clear: a still-demanding valuation, fierce competition in oral nicotine, and FDA regulatory uncertainty. Investors monitoring TPB should watch pouch-sales trends, quarterly EBITDA, any changes to analyst targets, and regulatory developments — all of which will determine whether the climb back to triple digits happens sooner, later, or not at all.

Tracking TPB with AI Daily Buy/Sell Signals

I've found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring stocks like TPB. The tool scans the market continuously and generates Buy, Sell, or Hold signals based on technical and AI-driven factors, giving me a clearer sense of shifting trends without constant manual checks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume